CJC-1295: What the Research Says About Growth Hormone Effects

What is CJC-1295 / Ipamorelin Stack?

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It works by binding to GHRH receptors on the pituitary gland, prompting the body to synthesize and release its own growth hormone (GH) in pulses, which in turn raises IGF-1 (insulin-like growth factor 1).

It is not synthetic HGH itself and does not introduce growth hormone directly into the body.

The name covers two structurally distinct forms, a distinction worth flagging immediately rather than glossing over: CJC-1295 with DAC, a long-acting version, and CJC-1295 without DAC (more precisely called Modified GRF (1-29)), a short-acting version.

These differ meaningfully in half-life and dosing frequency, and the naming is often used imprecisely; a full explanation follows in a dedicated section below.

In practice, CJC-1295 shows up in clinic and biohacking settings as an off-label, self- or clinic-administered peptide, discussed for body composition, recovery, sleep quality, and interest in age-related GH decline (sometimes called somatopause). It is not an FDA-approved medical treatment for any of these uses.

What the evidence actually supports

The mechanism itself is well-documented: a controlled human trial confirms CJC-1295 (with DAC) raises GH and IGF-1 levels. That is the strongest part of its evidence base.

Beyond that pharmacodynamic effect, most of the supportive human data comes from populations with diagnosed GH deficiency or from elderly subjects, not from healthy adults seeking body composition or recovery benefits. This distinction is easy to miss on commercial pages that present benefits as if they were demonstrated in the exact population using the product.

The research base itself is narrow. The core human pharmacokinetic data comes from a single key trial (Teichman et al., 2006), supplemented by mechanistic and animal-model research. Broader claims about muscle, fat loss, sleep, or anti-aging effects extrapolate from this limited foundation rather than resting on dedicated outcome studies. GH and IGF-1 explained

What the research shows

Not every claim made about CJC-1295 carries the same weight of evidence, and conflating them is where most marketing goes wrong. Here is how the human data actually breaks down, use case by use case.

Use Case | Evidence Rating | What the human data actually shows

—|—|—

GH and IGF-1 elevation | Moderate | Controlled human trial confirms the hormonal effect

Muscle growth / lean body composition | Limited | No dedicated trial; extrapolated from hormone rise

Fat metabolism | Limited | Mechanistically plausible, not directly tested

Sleep quality | Emerging | Clinic-observed only, no controlled sleep study

Recovery/energy | Emerging | Provider-reported timelines, no controlled data

Anti-aging / skin / cognitive function | Emerging | Called “hype zone” by the most rigorous source reviewed

Where the evidence is strongest

The one claim with a controlled human trial behind it is the pharmacodynamic effect itself, the rise in GH and IGF-1.

That is a Moderate rating, and it’s worth being precise about what “moderate” means here: it confirms CJC-1295 changes hormone levels in the bloodstream, not that those changes translate into any specific downstream benefit for a healthy adult.

Where the evidence thins out

Muscle growth and fat metabolism are both rated Limited. The logic connecting them to CJC-1295 is straightforward on paper: GH and IGF-1 are involved in protein synthesis and lipolysis, so raising them is assumed to move body composition. But that’s an inference, not a finding.

No controlled trial has measured actual muscle or fat mass change from CJC-1295 use in healthy adults. Supportive data in this space tends to come from studies of GH-deficient or elderly populations using different interventions entirely, which doesn’t transfer cleanly to someone using CJC-1295 off-label for aesthetic or fitness goals.

Where the evidence is weakest

Sleep quality, recovery/energy, and anti-aging/skin/cognitive claims are all rated Emerging, the lowest tier used in this profile. Sleep improvement claims lean on the fact that GH naturally peaks during deep sleep, but no controlled human sleep study has tested CJC-1295 directly.

Recovery and energy improvements reported in clinic settings are provider-observed timelines, not data from any trial with a control arm.

And anti-aging, skin, and cognitive benefits are the thinnest claims of all: no study in this research profile tests CJC-1295 for any of these outcomes directly, and the most rigorous independent editorial source in this space describes anti-aging claims specifically as sitting “in the hype zone.”

The bottom line on evidence quality

No source in this space, clinical, editorial, or clinic-run, provides FDA-approved or clinically validated efficacy data confirming muscle growth, fat loss, sleep improvement, recovery benefits, or anti-aging effects from CJC-1295. The single controlled human data point that exists measures hormone levels, not outcomes.

Everything past that point is either mechanistic reasoning or anecdotal, clinic-reported experience, and the two should not be mistaken for each other when weighing whether a specific claimed benefit is proven.

Does CJC-1295 Affect Testosterone or Other Hormones?

Does it raise testosterone?

No. CJC-1295 does not increase testosterone. Its mechanism runs through the GHRH receptor on the pituitary, driving GH and IGF-1 output, not the hypothalamic-pituitary-gonadal (HPG) axis that governs testosterone production. No source in this research reviewed reports testosterone suppression either. Testosterone simply sits outside what CJC-1295’s mechanism of action touches, in either direction.

Does it “mess with” hormones more broadly?

More precisely: it deliberately raises two hormones (GH and IGF-1) by design, and that’s the intended effect, not a side effect. The more relevant question is what happens to other hormones as a byproduct.

Here the Ipamorelin pairing is notable rather than concerning: Raun et al. (1998), a human study, found Ipamorelin stimulates GH release without a corresponding rise in ACTH, cortisol, or prolactin. That selectivity is part of why the stack is framed as targeted rather than broadly disruptive to the endocrine system.

It doesn’t mean the combination has zero hormonal footprint elsewhere, only that this specific concern (cortisol/prolactin spillover) is addressed by Ipamorelin’s receptor selectivity rather than by CJC-1295 itself.

The real hormone-adjacent concern: blood sugar

The more substantiated concern isn’t testosterone or cortisol, it’s glucose regulation. GH has a known relationship to insulin sensitivity, and a potential effect on insulin resistance and blood glucose is cited as a real risk factor rather than a hype-driven one, consistent with why uncontrolled diabetes is flagged elsewhere as a caution population.

This is the hormone-adjacent effect with the clearest support in the material reviewed, in contrast to testosterone, cortisol, or prolactin.

Thyroid hormones

No source in this research establishes an effect on thyroid hormones, positive or negative. Readers researching whether CJC-1295 might interact with thyroid function will not find that link supported anywhere in the material reviewed.

As with testosterone, the absence of a reported effect reflects the compound’s mechanism (pituitary GHRH receptor, GH/IGF-1 axis) rather than a gap in testing coverage described in these sources.

CJC-1295 With DAC vs. Without DAC: Why the Naming Gets Confused

Two names, one common mix-up

CJC-1295 with DAC is the long-acting form, built to persist in circulation for 6 to 8 days, which is why clinic protocols typically space doses once or twice weekly. That much is consistent across sources. Where things get muddled is the second product usually marketed as “CJC-1295 without DAC.”

Why “without DAC” is not just DAC-free CJC-1295

Most commercial and clinic pages describe this shorter-acting version as the same peptide with one component removed. Wikipedia, the highest scientific authority in this research set, states that framing is technically imprecise: the product commonly sold as “CJC-1295 without DAC” is actually Modified GRF (1-29), a related but structurally distinct molecule, not CJC-1295 minus an ingredient.

Wikipedia further notes this equivalence is repeated incorrectly in scientific literature itself, not just on consumer sites, which helps explain why the simplification is so widespread.

Why this distinction matters practically

For a reader deciding what they’re actually being offered, the practical takeaway is that these two products differ meaningfully in identity, not just duration. The DAC version’s 6 to 8 day half-life is well established.

The no-DAC/Mod GRF product’s half-life is reported inconsistently, with some sources citing roughly 30 minutes and others describing it more loosely as “a few hours.” No source in this research set provides a precise primary-research figure specific to the no-DAC molecule, so that number should be treated as unsettled rather than firmly established.

Anyone comparing product listings or dosing schedules should notice which name and which half-life claim a given source is actually using.

The History and Development of cjc 1295

Origin and early development

CJC-1295 was developed by ConjuChem Biotechnologies, a Canadian biotechnology company, as a longer-acting GHRH analog. The molecule was formally characterized in a 2005 identification paper by Jetté, Léger, and colleagues, which described its design and pharmacological rationale as a modified GHRH fragment with an extended circulating profile.

Clinical trial history

ConjuChem investigated CJC-1295 for lipodystrophy and GH deficiency, advancing the compound into Phase II human trials. Development was discontinued after a trial subject died; the attending physician attributed the death to likely pre-existing coronary artery disease unrelated to the drug, but the trial was halted as a precaution (detail covered in the safety section above).

No source in this research indicates the compound was ever resubmitted for further clinical development after that point.

The supporting research lineage

Beyond the Teichman 2006 human dosing study and the Raun 1998 Ipamorelin selectivity study already discussed, the broader evidence base draws on animal and mechanistic work: Alba and Fintini’s 2006 study in GHRH-knockout mice examined the GH axis in the absence of GHRH signaling, and Ionescu and Frohman’s 2006 work characterized the pulsatile pattern of GH release tied to sleep.

Together these studies form the citation backbone behind CJC-1295’s proposed mechanism, though most of the animal and identification-stage research predates and underlies the human pharmacokinetic data rather than testing downstream outcomes directly.

Chemical identity

CJC-1295 is registered under CAS number 446262-90-4, with molecular formula C165H269N47O46 and a molar mass of 3,647.25 g/mol. These identifiers, drawn from Wikipedia’s chemical data, are useful for distinguishing the compound from related GHRH analogs and from Modified GRF (1-29) in sourcing or literature searches.

Why interest persists

The broader rationale for continued interest in CJC-1295 and other GHRH analogs traces back to somatopause, the well-documented natural decline in growth hormone output with age. That decline, rather than any new efficacy finding, is the consistent thread connecting CJC-1295’s original clinical development to its current off-label and clinic-driven use.

Dosage and administration

Both forms of CJC-1295 are given by subcutaneous injection, typically into the abdomen or thigh, using an insulin-type syringe. Beyond route, how often it's injected depends entirely on which form is being discussed.

Frequency by form

The wide range on the no-DAC half-life (30 minutes versus "a few hours") reflects a genuine discrepancy across the sources reviewed, not a settled figure, and no study in this profile pins it down precisely.

Dose escalation pattern

Clinic materials reviewed describe a pattern of starting at a low dose and increasing it over several weeks to a maintenance dose, often run in cycles with defined on/off periods.

This escalation structure is a clinic convention observed in provider protocols, not a validated pharmacological schedule, and it is not being presented here as a recommendation. No controlled trial in this profile has tested dose-escalation timing, cycle length, or on/off scheduling against outcomes.

Time-to-effect, restated as observation

Clinic-reported timelines describe sleep changes appearing first, within roughly one to four weeks, with body composition changes reported later, around six to twelve weeks. These timeframes come from provider observation of patients on treatment, not from controlled trials measuring those endpoints, and should be read as anecdotal reporting rather than confirmed outcomes.

What's missing from the record

No FDA-approved dosing protocol exists for CJC-1295 in either form. Every frequency, escalation pattern, and timeline above reflects compounding-clinic convention rather than dosing established through clinical trials.

The one controlled human study in this profile (covered in the evidence section) tested a single injection under research conditions, not a repeating maintenance schedule, so it does not validate any of the ongoing-use patterns described by clinics.

Safety and side effects

Commonly reported effects

Across clinic and retail sources, the most frequently cited side effects are injection-site reactions (redness, irritation, swelling), water or fluid retention, headache, flushing, joint or muscle pain, nausea, and appetite changes. These are described consistently as the expected, lower-severity effects of GH/IGF-1 elevation rather than rare reactions, though no source quantifies exact frequency rates.

More significant concerns

Two effects are flagged with more weight. First, a potential impact on insulin resistance and blood glucose, consistent with GH’s known role in glucose metabolism, listed as a real concern rather than a theoretical one. Second, numbness or tingling resembling carpal tunnel symptoms, thought to relate to fluid retention affecting nerve compression.

Neither is described with an incidence rate, only as a recognized risk category clinicians and regulators list.

What long-term safety data actually shows

Long-term human safety data is described across sources as limited or thin. The longest concrete, published data point in this profile is the 28-day window of elevated IGF-1 following repeated dosing in the Teichman human trial, referenced earlier.

That figure represents the outer edge of what has actually been measured in controlled human research; nothing in the reviewed sources documents monitored human safety outcomes beyond that window.

Why regulators flag it

The FDA’s Category 2 bulk drug substance listing cites specific safety-risk concerns behind restricting compounding use: immunogenicity, impurities, aggregation, and potential cardiac adverse events. These are regulatory concerns tied to manufacturing and biological risk profile, not confirmed clinical outcomes from a specific trial.

The discontinued Phase II trial

CJC-1295 was investigated in a Phase II trial for lipodystrophy and GH deficiency. The trial was halted after a participant died during the study. The attending physician attributed the death to likely pre-existing, asymptomatic coronary artery disease and plaque rupture, unrelated to the drug itself.

Even with that attribution, researchers stopped the trial as a precaution rather than continuing. This remains a documented part of the compound’s clinical history, not a resolved or dismissed event, and it sits alongside the broader pattern of thin long-term human safety data described above.

Who should not use CJC-1295 / Ipamorelin Stack

Legal status

CJC-1295 is not FDA-approved for any use, and its legal status is best understood as a timeline rather than a fixed answer.

October 2023: Category 2 classification

The FDA placed CJC-1295 on its Category 2 list of bulk drug substances that cannot be used in 503A compounding.

Category 2 substances are those the agency has identified as carrying safety concerns significant enough to bar them from compounding pharmacies, even though a licensed pharmacy would otherwise be able to prepare a peptide like this on a prescription basis.

The cited concerns include immunogenicity, impurities introduced during synthesis, aggregation, and potential cardiac adverse events, the same cardiac concern noted earlier in this article's discussion of regulatory flags.

April 2026: a reclassification round that didn't include CJC-1295

More than two years later, the FDA reclassified 12 peptides out of Category 2, moving them toward broader compounding eligibility. CJC-1295 was not among them. That's a meaningful data point: it shows the agency is actively revisiting this category rather than leaving it static, but it also shows CJC-1295 specifically wasn't judged ready to move.

July 2026: not considered

A subsequent FDA advisory committee meeting reviewed related substances but did not take up CJC-1295 at all. That's distinct from a denial. It simply wasn't on the agenda, which leaves its status unresolved rather than settled in either direction.

What this means in practice

Taken together, these three dates describe a compound that remains in a restricted compounding gray zone as of the most recent reporting available. Legitimate, prescription-based access through a compounding pharmacy is constrained by the Category 2 listing, and nothing in the record so far shows that changing.

Whether that shifts in a future reclassification cycle isn't something this timeline can predict. Given how much movement occurred in just the April and July 2026 windows, readers should verify the FDA's current bulk drug substance list directly rather than relying on any single article, including this one, since status here is actively evolving.

Competitive sport status

Separate from FDA compounding rules, CJC-1295 appears on the World Anti-Doping Agency's Prohibited List, meaning athletes subject to WADA testing are barred from using it regardless of how the FDA's compounding classification resolves.

how peptide compounding works

Often used with

CJC-1295 rarely appears in isolation in the sources reviewed. This section describes what's actually discussed alongside it, not a recommendation to combine compounds. Ipamorelin Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist, mechanistically distinct from CJC-1295's GHRH-receptor pathway. Raun et al. (1998) found Ipamorelin raised GH without significantly raising ACTH, cortisol, or prolactin. without significantly raising ACTH, cortisol, or prolactin, a selectivity profile that di

Frequently asked questions